Friday, 28 November 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 28 November 2025
News

Novo gamble fails to pay off

 Posted November 27 2025 PM

Semaglutide can’t cure Alzheimer’s after all. The GLP-1 agonist failed to reduce disease progression in two phase 3 trials, Novo Nordisk announced this week.

The research had always been a long shot. It was a “lottery ticket”, Novo Executive Vice President for Product and Portfolio Strategy, Ludovic Helfgott, told Reuters two months ago. However, markets were still disappointed: Novo’s stock fell about six per cent down on both the Danish and US exchanges.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (16)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (3)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.